Current Report Filing (8-k)
March 14 2019 - 5:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
_________________
Date of Report (Date of earliest event reported):
March 13, 2019
Alliqua BioMedical, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-36278
|
|
58-2349413
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2150 Cabot Blvd., West
Suite B
Langhorne, PA
|
|
19047
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (215) 702-8550
Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 13, 2019, Joseph Warusz delivered his resignation as
Chief Financial Officer of Alliqua Biomedical, Inc. (the “Company”), effective March 18, 2019. Mr. Warusz will continue
to serve as the Company’s Chief Financial Officer through March 18, 2019.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ALLIQUA BIOMEDICAL, INC.
|
|
|
|
|
|
|
Dated: March 14, 2019
|
By:
|
/s/ David I. Johnson
|
|
|
Name: David I. Johnson
|
|
|
Title: Chief Executive Officer
|
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From Apr 2024 to May 2024
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From May 2023 to May 2024